January 1, 2001Open Access

Angiotensinogen Gene Variation and Hypertension in a Cohort Study in Japanese.

Q: What is the clinical evidence from this study?

Study design: Cohort. Population: Hypertension (n=1001). Intervention: M235T polymorphism of the angiotensinogen (AGT) gene (MT genotype) vs. MM genotype. Primary outcome: Incidence of hypertension (RR 1.49, 95% CI 0.49 - 4.53, p=not significant).

Key Result

The M235T polymorphism of the angiotensinogen gene was not significantly associated with the incidence of hypertension, with an adjusted relative risk of 1.49 for the MT genotype compared to the MM genotype.

Study Design

Type

Cohort (n=1,001)

Multicenter

PICO

Population

1,001 Japanese workers without baseline hypertension were followed for 6 years to evaluate the association between the angiotensinogen gene M235T polymorphism and incident hypertension.

Exposure / Comparator

M235T polymorphism of the angiotensinogen (AGT) gene (MT genotype) vs MM genotype

Primary Outcome

Incidence of hypertension — RR 1.49 (0.49 - 4.53), p=not significant

Main Result

Relative Risk: 1.49 (95% CI 0.49–4.53)

p-value: p=not significant

Limitations

Retrospective cohort study design, which may have lower adequacy of results compared to a prospective cohort study
Potential need to evaluate which confounding factors should be corrected
Potential publication bias in the broader literature

Abstract

Many recent case-control studies have suggested a significant relationship between M235T (the substitution of threonine for methionine at position 235 codon) polymorphism of the angiotensinogen (AGT) gene and hypertension. To investigate whether the M235T polymorphism of AGT gene affects the incidence of hypertension, a retrospective cohort study was performed among Japanese workers. The subjects were Japanese workers at an occupational site in Shimane Prefecture in Japan. The baseline data were set at the received regular health examination in 1992, and a retrospective cohort study was performed for analyzing the incidence of hypertension in 1998. The rates of M235M (MM), M235T (MT) and T235T (TT) genotypes were 4%, 32% and 64%, respectively. The relative risks of MT and TT against MM for the incidence of hypertension by single variance analysis were 1.47 95% confidence interval (CI) 0.50 - 4.33 and 1.35 (95% CI 0.47 - 3.90), respectively. The relative risks of MT and TT against MM for the incidence of hypertension, adjusted for sex, age, body mass index, fasting glucose and cigarette smoking, drinking and exercise in 1992, were 1.49 (95% CI 0.49 - 4.53) and 1.25 (95% CI 0.42 3.74), respectively. The data from this study suggest that the M235T polymorphism of AGT gene has a weak role in the manifestation of hypertension. Further comprehensive studies are needed to resolve this issue.

Bookmark

View Full Paper

Cite This Study

Kishimoto et al. (Mon,) conducted a cohort in Hypertension (n=1,001). M235T polymorphism of the angiotensinogen (AGT) gene (MT genotype) vs. MM genotype was evaluated on Incidence of hypertension (RR 1.49, 95% CI 0.49 - 4.53, p=not significant). The M235T polymorphism of the angiotensinogen gene was not significantly associated with the incidence of hypertension, with an adjusted relative risk of 1.49 for the MT genotype compared to the MM genotype.

synapsesocial.com/papers/6a23853498edd3e1959ed083 https://doi.org/https://doi.org/10.2188/jea.11.115

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Bookmark

View Full Paper